Directory Listing

• market.html
  

Description of the invention:
clikc inside the box to read more and remove the mouse from the box to continue scrowlling over the site
A new potent agent for neurogenesis in the hypocampus combination. The present invention relates to a new potent and valuable neurotrophic composition which stimulates human-derived neural stem cells in the hippocampus to form new neurons in vitro and stimulates neurogenesis in mouse hippocampus under the same pathways in vivo. It also acts on human brain undifferentiated neurons stem-cells (hNSCs) causing their proliferation, a rare finding on nerve growth factors studys. It has no or low toxicity, another advantage is once a day protocol with little to no side-effects. The present combination has the potential use of treating depression and cognitive impairment. The invention also shows to exceed Prozac(fluoxetine) neurotrophic proprieties in the hypothalamus on mice and non-human primates to an ample extend. It is safe such that does not trigger the benign proliferation of astrocytes, which already occurs with age and it is considered a maladaption. BUSPIRONE: Buspirone is a drug from the aryl(guetaryl)piperazines that contains an active 1-(2-pyrimidinyl)-piperazine metabolite . Buspirone processes partial agonist activity at 5HT-A1 receptors and a potent one at presynaptic 5HT-A1 autoreceptors. Which makes it a SRA(Serotonin releasing agent) after desensitization of the autoreceptors. Buspirone also blocks inhibitory presynaptic D2 autoreceptors while the piperazine moiety inhibits the a2-andrenoreceptors, only at higher doses buspirone antagonizes postsynaptic D2 receptors. Low doses of buspirone act therefor as a euphoriant; increasing noradrenergic and dopaminergic activity, while higher doses functioning more towards typical anti-psychotics. Demonstration of such dynamics have been reported in humans by the co-administration of methamphetamine after either a low or high dose of buspirone. The low buspirone dose increases the subjective high of the methamphetamine drug (as reported by users), while large doses creating the opposite effect, decreasing the reported subjective high of the drug. Buspirone in all regards has been mostly forgotten in research and is listed only as a augmentative anti-depressant with poor results. However Buspirone co-administer on different embodiment's, acts similar to short-lived euphoriants. MELATONIN: Melatonin (N-acetyl-5-methoxytryptamine, MLT) discovered in 1958 is versatile neurohormone which functions in many ways as an powerful (in fact the most powerful) antioxidant with (1) direct scavenging of reactive oxygen (ROS) and reactive nitrogen (RNS) species, (2) acceleration of antioxidant enzymes activity, (3) protection against oxidative damage, (4) synergistic effects with other antioxidants, (5) improvement of the electron transport efficiency in the mitochondrial respiratory chain, limiting the overproduction of free radicals by reducing electron leakage Resveratrol was an infamous anti-aging drug partly working due to its SIRT1 activation. Melatonin is also a potent SIRT1 activator, surpassing Resveratrol. Resveratrol become a popular compound despite its failure to translate any kind of longevity benefits from lab animals to humans. Contrastingly melatonin retains its potency during translation research from animal labs to humans, with extended anti-aging benefits exceeding those of Resveratrol. The present invention is a combination of BUSPIRONE and MELATONIN for their potent anti-apoptotic, pro-survival, neuroprotective and neurotrophic signaling, inducing the specific proliferation of undifferentiated human neuron stem cells (hNSCs).

IMAGE 1 Neural-stem cells within the dentate gyrus
	Visualization of the increase in the rat neural-stem cells within the dentate gyrus after 28 days of treatment, exceeding Prozac treatment.
Multi-Target of ageing dysfunctions STEM-CELL DEPLETION is a HALLMARK OF AGEING